| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282409 | Clinical Gastroenterology and Hepatology | 2015 | 10 Pages |
Abstract
Careful monitoring of patients with CHB who did not meet treatment criteria at presentation permits timely initiation of treatment, with a low risk of adverse clinical outcomes, based on a retrospective study with a median follow-up period of 4.3 years. These findings indicate that current guidelines for initiating treatment are appropriate.
Keywords
CHBULNAPASLInactive carrierHBsAgEASLALTAASLDHBeAgHCCAlanine aminotransferaseHepatitis B surface antigenAsian Pacific Association for the Study of the LiverAmerican Association for the Study of Liver DiseaseEuropean Association for the Study of the Liverimmune toleranceUpper limit of normalCancerAntiviral agentHBV infectionManagementHepatitis B e antigenchronic hepatitis BHBVpolymerase chain reactionPCRhepatitis B virusHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Suna Yapali, Nizar Talaat, Robert J. Fontana, Kelly Oberhelman, Anna S. Lok,